Simple Summary Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the
treatment of hematological malignancies but is often associated with significant adverse …

Improving CAR-T cell therapy for solid tumors requires a better understanding of CAR
design and cellular composition. Here, we compared second-generation (BBζ and 28ζ) with …

Chimeric antigen receptors (CAR) are generated by linking extracellular antigen recognition
domains with one or more intracellular signaling domains derived from the T-cell receptor …

Abstract CAR-T cells are T cells expressing a chimeric antigen receptor (CAR) rendering
them capable of killing tumor cells after recognition of a target antigen. CD19 CAR-T cells …

One of the major hurdles that has hindered the success of chimeric antigen receptor (CAR) T
cell therapies against solid tumors is on-target off-tumor (OTOT) toxicity due to sharing of the …

Genetically modified autologous T cells have become an established immunotherapy in the
fight against cancer. The manufacture of chimeric antigen receptor (CAR) and αβ-T cell …

Natural Killer cells (NK cells) are a key component of the innate immune system and are key
effectors of immunosurveillance. NK cells not only have the inherent ability to directly kill …

One of the major barriers that have restricted successful use of chimeric antigen receptor
(CAR) T cells in the treatment of solid tumors is an unfavorable tumor microenvironment …

Solid tumors account for approximately 90% of all adult human cancers. As such, the
development of novel cellular therapies has become of increasing importance to target solid …

Bioprocessing applications for cells and biologics have dramatically increased the number
of samples needed to test for cell therapy and immunotherapy. The cell counting time is a …